May 15, 2020 7:00am EDT Can-Fite Announces Pre-IND Submission to U.S. FDA for Piclidenoson in the Treatment of COVID-19 Infected Patients with Moderate-to-Severe Symptoms
Apr 14, 2020 7:00am EDT Can Fite to Conduct Investor Call to Review Positive Phase II NASH Data on Thursday, April 16, 2020 at 4:05 p.m. ET
Apr 13, 2020 6:30am EDT Can Fite Received Approval for COVID-19 Clinical Trial in Israel, Patient Enrollment and Dosing to Commence Immediately
Apr 07, 2020 9:00am EDT Can-Fite Reports Positive Top Line Results from its Phase II NASH Study with Namodenoson
Mar 30, 2020 7:00am EDT Can-Fite Implements Interim Analysis for its Phase III Psoriasis Trial with Data Expected Q4 2020
Mar 27, 2020 7:00am EDT Can-Fite Reports 2019 Financial Results & Provides Clinical Development Update
Mar 23, 2020 7:45am EDT Can-Fite: Piclidenoson is Submitted for Compassionate Use Treatment for Coronavirus Patients in Israel
Mar 18, 2020 7:00am EDT Can-Fite to Participate in Digital Bio-Europe Spring Partnering Conference; Looks to Partner on Co-Development of Piclidenoson for Coronavirus Treatment
Mar 16, 2020 7:00am EDT Can-Fite: Progress in Compassionate Use Program Treating Advanced Liver Cancer Patients with Namodenoson
Mar 13, 2020 7:00am EDT Can-Fite to Explore the anti-Coronavirus Effects of Piclidenoson in Collaboration with Lewis Katz School of Medicine at Temple University
